Intellectual Property Stream

One of the key assets of NovaThera is its intellectual property pipeline.

The founding terms with Imperial College secure rights to past, present and future intellectual property emanating from the Tissue Engineering and Regenerative Medicine group. The intellectual property framework confers to NovaThera first rights of refusal to commercially exploit IP arising from research in TERM on an ongoing, renewable basis. NovaThera continues to exercise its rights in this regard.

NovaThera is also the lead commercial partner in a DTI sponsored consortium focussed on the development of practical applications of stem cell technologies (see Press Releases). The consortium features the Universities of Southampton, Cardiff, Imperial, Cambridge, Manchester and the Roslin Institute. NovaThera has first rights of refusal to commercially exploit technologies developed through the consortium research program.

NovaThera has also obtained an exclusive license in the regenerative medicine, wound care and dermatology fields to the key sol-gel bioactive glass (“TheraGlass®”) patent portolios of both Imperial College and USBiomaterials Corporation.

NovaThera will continue to either develop or acquire Intellectual Property covering key aspects of technology which fit within current and future product development activities.